SG Americas Securities LLC Invests $169,000 in Aura Biosciences, Inc. (NASDAQ:AURA)

SG Americas Securities LLC purchased a new stake in Aura Biosciences, Inc. (NASDAQ:AURA) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 18,969 shares of the company’s stock, valued at approximately $169,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. American Century Companies Inc. acquired a new stake in Aura Biosciences in the second quarter valued at approximately $119,000. American International Group Inc. lifted its position in shares of Aura Biosciences by 27.4% during the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after buying an additional 3,782 shares in the last quarter. Virtu Financial LLC acquired a new stake in Aura Biosciences in the 1st quarter valued at $144,000. Rhumbline Advisers increased its holdings in Aura Biosciences by 39.6% in the 2nd quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock worth $480,000 after acquiring an additional 18,011 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Aura Biosciences by 14.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock worth $487,000 after acquiring an additional 8,194 shares in the last quarter. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Aura Biosciences Price Performance

Aura Biosciences stock opened at $11.40 on Thursday. The stock has a market cap of $564.79 million, a price-to-earnings ratio of -6.13 and a beta of 0.37. The firm has a 50 day simple moving average of $8.87 and a 200-day simple moving average of $8.15. Aura Biosciences, Inc. has a 1-year low of $5.99 and a 1-year high of $12.38.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.04. Equities analysts expect that Aura Biosciences, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AURA has been the topic of several recent analyst reports. BTIG Research increased their price objective on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a report on Friday, October 18th. JMP Securities raised their target price on Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a research report on Friday, September 13th. HC Wainwright boosted their price target on shares of Aura Biosciences from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, October 18th. Scotiabank increased their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a report on Friday, October 18th. Finally, Evercore ISI upgraded Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $23.00.

Insider Activity

In related news, CTO Mark Plavsic sold 7,383 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total transaction of $72,722.55. Following the completion of the transaction, the chief technology officer now directly owns 121,132 shares in the company, valued at $1,193,150.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, CFO Julie B. Feder sold 25,131 shares of Aura Biosciences stock in a transaction on Friday, October 18th. The stock was sold at an average price of $12.03, for a total value of $302,325.93. Following the completion of the transaction, the chief financial officer now directly owns 134,276 shares in the company, valued at approximately $1,615,340.28. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CTO Mark Plavsic sold 7,383 shares of the business’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total value of $72,722.55. Following the transaction, the chief technology officer now directly owns 121,132 shares of the company’s stock, valued at $1,193,150.20. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 57,506 shares of company stock valued at $675,952. 5.40% of the stock is currently owned by corporate insiders.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.